The CDCM provides the organizational and physical infrastructure to support investigator-initiated clinical translational studies on cell and gene therapy from initial discovery through completion of phase I/II proof-of-concept clinical studies. During the development of cell and gene therapy products for these trials, value is created in the form of intellectual property, manufacturing practices, regulatory affairs development and quite importantly, clinical practice and data.
The CDCM hosted its first symposium to bring together basic scientists, translational biologists and clinicians in the Bay Area and California to highlight existing first-in-human cell and gene therapies currently under development at Stanford.
